130 related articles for article (PubMed ID: 7963729)
21. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.
Goepfert PA; Tomaras GD; Horton H; Montefiori D; Ferrari G; Deers M; Voss G; Koutsoukos M; Pedneault L; Vandepapeliere P; McElrath MJ; Spearman P; Fuchs JD; Koblin BA; Blattner WA; Frey S; Baden LR; Harro C; Evans T;
Vaccine; 2007 Jan; 25(3):510-8. PubMed ID: 17049679
[TBL] [Abstract][Full Text] [Related]
22. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative thais.AFRIMS-RIHES Vaccine Evaluation Group. Armed Forces Research Institute of Medical Sciences and the Research Institute for Health Sciences.
Nitayaphan S; Khamboonruang C; Sirisophana N; Morgan P; Chiu J; Duliege AM; Chuenchitra C; Supapongse T; Rungruengthanakit K; deSouza M; Mascola JR; Boggio K; Ratto-Kim S; Markowitz LE; Birx D; Suriyanon V; McNeil JG; Brown AE; Michael RA
Vaccine; 2000 Feb; 18(15):1448-55. PubMed ID: 10618542
[TBL] [Abstract][Full Text] [Related]
23. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine.
Sanchez-Pescador L; Burke RL; Ott G; Van Nest G
J Immunol; 1988 Sep; 141(5):1720-7. PubMed ID: 2842401
[TBL] [Abstract][Full Text] [Related]
24. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine.
Schwartz DH; Gorse G; Clements ML; Belshe R; Izu A; Duliege AM; Berman P; Twaddell T; Stablein D; Sposto R
Lancet; 1993 Jul; 342(8863):69-73. PubMed ID: 8100910
[TBL] [Abstract][Full Text] [Related]
25. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants.
Valensi JP; Carlson JR; Van Nest GA
J Immunol; 1994 Nov; 153(9):4029-39. PubMed ID: 7930610
[TBL] [Abstract][Full Text] [Related]
26. Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.
Leroux-Roels I; Koutsoukos M; Clement F; Steyaert S; Janssens M; Bourguignon P; Cohen K; Altfeld M; Vandepapelière P; Pedneault L; McNally L; Leroux-Roels G; Voss G
Vaccine; 2010 Oct; 28(43):7016-24. PubMed ID: 20728522
[TBL] [Abstract][Full Text] [Related]
27. Maternal monoclonal antibody to the V3 loop alters specificity of the response to a human immunodeficiency virus vaccine.
Jelonek MT; Maskrey JL; Steimer KS; Potts BJ; Higgins KW; Keller MA
J Infect Dis; 1996 Oct; 174(4):866-9. PubMed ID: 8843232
[TBL] [Abstract][Full Text] [Related]
28. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques.
Phillips B; Van Rompay KKA; Rodriguez-Nieves J; Lorin C; Koutsoukos M; Tomai M; Fox CB; Eudailey J; Dennis M; Alam SM; Hudgens M; Fouda G; Pollara J; Moody A; Shen X; Ferrari G; Permar S; De Paris K
J Virol; 2018 Oct; 92(20):. PubMed ID: 30089691
[TBL] [Abstract][Full Text] [Related]
30. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320.
McCormack S; Tilzey A; Carmichael A; Gotch F; Kepple J; Newberry A; Jones G; Lister S; Beddows S; Cheingsong R; Rees A; Babiker A; Banatvala J; Bruck C; Darbyshire J; Tyrrell D; Van Hoecke C; Weber J
Vaccine; 2000 Jan; 18(13):1166-77. PubMed ID: 10649617
[TBL] [Abstract][Full Text] [Related]
31. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
[TBL] [Abstract][Full Text] [Related]
32. Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF.
Liao HX; Cianciolo GJ; Staats HF; Scearce RM; Lapple DM; Stauffer SH; Thomasch JR; Pizzo SV; Montefiori DC; Hagen M; Eldridge J; Haynes BF
Vaccine; 2002 May; 20(17-18):2396-403. PubMed ID: 12009296
[TBL] [Abstract][Full Text] [Related]
33. Combination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulation.
Kleinerman ES; Meyers PA; Raymond AK; Gano JB; Jia SF; Jaffe N
J Immunother Emphasis Tumor Immunol; 1995 Apr; 17(3):181-93. PubMed ID: 7613644
[TBL] [Abstract][Full Text] [Related]
34. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
Bower JF; Green TD; Ross TM
Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
[TBL] [Abstract][Full Text] [Related]
35. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
[TBL] [Abstract][Full Text] [Related]
36. International clinical trials of HIV vaccines: II. phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China.
Li D; Forrest BD; Li Z; Xue P; Hanson CV; Duan S; Cheng H; Li M; Wang CY; Koff WC
Asian Pac J Allergy Immunol; 1997 Jun; 15(2):105-13. PubMed ID: 9346275
[TBL] [Abstract][Full Text] [Related]
37. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators.
Borkowsky W; Wara D; Fenton T; McNamara J; Kang M; Mofenson L; McFarland E; Cunningham C; Duliege AM; Francis D; Bryson Y; Burchett S; Spector SA; Frenkel LM; Starr S; Van Dyke R; Jimenez E
J Infect Dis; 2000 Mar; 181(3):890-6. PubMed ID: 10720509
[TBL] [Abstract][Full Text] [Related]
38. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
AIDS Vaccine Evaluation Group 022 Protocol Team
J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
[TBL] [Abstract][Full Text] [Related]
39. Mixed adjuvant formulations reveal a new combination that elicit antibody response comparable to Freund's adjuvants.
Lai RP; Seaman MS; Tonks P; Wegmann F; Seilly DJ; Frost SD; LaBranche CC; Montefiori DC; Dey AK; Srivastava IK; Sattentau Q; Barnett SW; Heeney JL
PLoS One; 2012; 7(4):e35083. PubMed ID: 22509385
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration.
Lubeck MD; Natuk RJ; Chengalvala M; Chanda PK; Murthy KK; Murthy S; Mizutani S; Lee SG; Wade MS; Bhat BM
AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1443-9. PubMed ID: 7888199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
